This was the turning point in defining the biological role of IgE and, in 2003, the introduction of omalizumab, a humanised mAb that selectively binds to IgE, for the treatment of moderate to severe persistent allergic asthma (and later also chronic idiopathic urticaria), marked a milestone in both mAb and anti-IgE therapy. Here, IGHE is linked to allergic asthma.